Pancreatic Cancer

Cooperman, Avram M.

doi:10.1016/s0039-6109(05)70143-2

Cited by 67 publications

(21 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early detection of this disease is not possible in spite of significant diagnostic tools. The effective therapy, surgery, is limited to about 25% of the cases and often is unable to prevent cancer recurrence in these patients [67]. Much remains to be understood about the natural course and biology of this disease.…”

Section: Discussionmentioning

confidence: 99%

Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer

Candido

Maestro²,

Polesel³

et al. 2014

Oncotarget

115

View full text Add to dashboard Cite

Cancer remains one of the major cause of death in the Western world. Although, it has been demonstrated that new therapies can improve the outcome of cancer patients, still many patients relapse after treatment. Therefore, there is a need to identify novel factors involved in cancer development and/or progression. Recently, neutrophil gelatinase-associated lipocalin (NGAL) has been suggested as a key player in different cancer types. Its oncogenic effect may be related to the complex NGAL/MMP-9. In the present study, NGAL was analyzed at both transcript and protein levels in different cancer types by analysing 38 public available microarray datasets and the Human Protein Atlas tool.NGAL transcripts were significantly higher in the majority of solid tumors compared to the relative normal tissues for every dataset analyzed. Furthermore, concordance of NGAL at both mRNA and protein levels was observed for 6 cancer types including bladder, colorectal, liver, lung, ovarian, and pancreatic. All metastatic tumors showed a decrease of NGAL expression when compared to matched primary lesions.According to these results, NGAL is a candidate marker for tumor growth in a fraction of solid tumors. Further investigations are required to elucidate the function of NGAL in tumor development and metastatic processes.

show abstract

Section: Discussionmentioning

confidence: 99%

Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer

Candido

Maestro²,

Polesel³

et al. 2014

Oncotarget

115

View full text Add to dashboard Cite

show abstract

“…D ue to the absence of specific symptoms, the lack of early detection techniques, pancreatic cancer is usually diagnosed at advanced and metastatic stages and is not resected by surgery (1, 2). To date, chemo- and radiation-therapy has only limited success because of high resistance (3). Unfortunately, only less than 15% of all pancreatic cancer patients have a chance for surgical resection, after which 5-year survival rarely succeed to 20-25% (4, 5).…”

Section: Introductionmentioning

confidence: 99%

Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy

Yang

et al. 2016

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

The IL-6/GP130/STAT3 pathway is crucial for tumorigenesis in multiple cancer types, including pancreatic cancer and presents as a viable target for cancer therapy. We reported Bazedoxifene, which is approved as a selective estrogen modulator by FDA, as a novel inhibitor of IL-6/GP130 protein−protein interactions using multiple ligand simultaneous docking and drug repositioning approaches. STAT3 is one of the major downstream effectors of IL-6/GP130. Here, we observed Bazedoxifene inhibited STAT3 phosphorylation and STAT3 DNA binding, induced apoptosis, and suppressed tumor growth in pancreatic cancer cells with persistent IL-6/GP130/STAT3 signaling in vitro and in vivo. In addition, IL-6 but not INF-γ rescued Bazedoxifene-mediated reduction of cell viability. Bazedoxifene also inhibited STAT3 phosphorylation induced by IL-6 and IL-11, but not by OSM or STAT1 phosphorylation induced by INF-γ in pancreatic cancer cells, suggesting that Bazedoxifene inhibits GP130/STAT3 pathway mediated by IL-6 and IL-11. Furthermore, Bazedoxifene combined with paclitaxel or gemcitabine synergistically inhibited cell viability and cell migration in pancreatic cancer cells. These results indicate that Bazedoxifene is a potential agent and can generate synergism when combined with conventional chemotherapy in human pancreatic cancer cells and tumor Xenograft in mice. Therefore, our results support that Bazedoxifene as a novel inhibitor of GP130 signaling and may be a potential and safe therapeutic agent for human pancreatic cancer therapy.

show abstract

“…Operative preferences and techniques for PDR are many and for the most part do not impact on long-term survival [2] The ultimate determinant of outcome is systemic metastases present long before tumor discovery [2, 6]. Reconstruction after resection is invariably done by proximal biliary and pancreatic enteric anastomoses and distal gastric or duodenal enteric anastomoses.…”

Section: Discussionmentioning

confidence: 99%

“…Local recurrence of pancreatic cancer causing obstruction of the biliary or gastric anastomoses and requiring surgery is not frequent. At least 30% of PDR done for pancreatic cancer will recur locally in the bed of resection [2, 10]. When intervention is needed for biliary obstruction, the percutaneous approach is preferred.…”

Section: Discussionmentioning

confidence: 99%

“…Alimentary reconstruction during pancreaticoduodenal resection invariably places the gastric or duodenal jejunal anastomoses distal to the biliary and pancreatic anastomoses [1, 2]. Despite absence of supporting literature this is done for alleged fears of pancreatic and biliary fistulas that will delay oral feedings and prolong hospitalization.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Proximal Gastrojejunal Reconstruction after Pancreaticoduodenal Resection

Wayne

Cooperman

Narang³

et al. 2012

International Journal of Surgical Oncology

View full text Add to dashboard Cite

Introduction. Reconstruction by proximal gastrojejunostomy, and distal biliary and pancreatic anastomoses is infrequently used after resection of the head of the pancreas because of fear of fistulas and cholangitis. Pancreaticoduodenectomy is being performed more frequently for cystic malignant and premalignant lesions. Because of this there is a need for endoscopic visualization and biopsy of the residual pancreatic duct, since multi-centricity is characteristic of some of these malignancies. Since endoscopic access of the bile duct and pancreatic duct is difficult and unsuccessful in 50–70% after B II or Roux Y reconstruction, we prospectively studied the merit and complications (early and late) of proximal gastrojejunal (PGJ) reconstruction after pancreaticoduodenal resection. Material and Methods. Thirty nine consecutive, non-radomized patients underwent pancreaticoduodenectomy and PGJ reconstruction over 14 mos. There were 21 males and 18 females. Results. 7 patients with IPMN have undergone repeat CT scanning for surveillance, with 3 requiring repeat EUS and ERCP. There were no technical difficulties accessing the pancreas or the pancreatic duct, supporting the PGJ reconstruction. Conclusion. Proximal gastrojejunal reconstruction following pancreaticoduodenal resection may be safely done with similar morbidity to traditional pancreaticojejunal reconstructions. PGJ reconstruction may be of greater value when direct visual access to the bile duct or pancreatic duct is necessary, and should be considered when doing resection for mucinous cysts or IPMN of the head of the pancreas.

show abstract

Pancreatic Cancer

Cited by 67 publications

References 87 publications

Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer

Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer

Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy

Proximal Gastrojejunal Reconstruction after Pancreaticoduodenal Resection

Contact Info

Product

Resources

About